In recent years, a number of research findings has renewed interest in the possible role of serotonin (5-HT) in the pharmacology of schizophrenia. Atypical antipsychotics that potently block 5-HT receptors have been shown to be at least as effective as classical antipsychotics as well as producing fewer extrapyramidal side-effects. In addition, molecular biological studies have suggested that allelic variations of 5-HT receptor genes may affect both susceptibility to schizophrenia and clinical response to atypical antipsychotics. Building on these findings, this article proposes that 5-HT receptors are critical sites of antipsychotic action, and examines the implications of this to the treatment and pathophysiology of schizophrenia. Possible pharmacological mechanisms underlying the clinical efficacy of 5-HT blocking antipsychotics are discussed, and the potential of functional neuroimaging techniques to further elucidate these mechanisms is emphasized.
Abi-Dargham A., Terriere D., Zea-Ponce Y., Al-Tikriti M., Baldwin R., Hoffer D., Charney D., Laruelle M., Leysen J.E., Innis R., Mertens J. (1995) [123I]5-I-R91150: a new SPECT tracer for the serotonin 5-HT2A receptors. J Nucl Med36:164P
2.
Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jr, Jones E.G. (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics . Archs Gen Psychiat52: 258-266
3.
Altar C.A., Wasley A.M., Neale R.F., Stone G.A. (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull16: 517-525
4.
Arora R.C., Meltzer H.Y. (1991) Serotonin (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect85: 19-29
5.
Arranz M., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P., Kerwin R. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet346: 281-282
6.
Ashby C.R., Jr, Wang R.Y. (1990) Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res506: 346-348
7.
Azmitia E.C., Whitaker-Azmitia P.M. (1991) Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiat52 (Suppl. 12) : 4-16
8.
Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. and the Olanzapine HGAD Study Group ( 1996) Olanzapine versus placebo and haloperidol—acute phase results of the North American double-blind olanzepine trial. Neuropsychopharmacology14: 111-123
9.
Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. (1992) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci12: 924-929
10.
Bersani G., Grspini A., Marini S., Pasini A., Valducci M., Ciani N. (1990) 5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmac13: 500-506
11.
Bleich A., Brown S.L., Kahn R., van Praag H.M. (1988) The role of serotonin in schizophrenia. Schizophr Bull14: 297-315
12.
Blue M.E., Yagaloff K.A., Mamounas L.A., Hartig P.R., Molliver M.E. (1988) Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex. Brain Res453: 315-328
13.
Bobker D.H., Williams J.T. (1990) Serotonin-mediated inhibitory post-synaptic potential in guinea-pig prepositus hypoglossi and feedback inhibition by serotonin. J Physiol Lond422: 447-462
14.
Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.P., Middlemiss D.N., Mylecharane E.J., Richardson B.P., Saxena P.R. (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology25: 563-576
15.
Breier A. (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res14: 187-202
16.
Breier A., Kirkpatrick B., Buchanan R.W. (1993) Clozapine attenuates meta-chlorophenylpiperazine (m-CPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiat34: 492-494
17.
Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N.P., Kerwin R.W. (1995) Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride—an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology117: 55-61
18.
Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Kerwin R.W. (1996) Reduced benzodiazepine receptor binding correlates with severity of psychotic symptoms in schizophrenia. Am J Psychiat, in press
19.
Canton H., Verriele L., Colpaert F.C. (1990) Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Europ J Pharmac191: 93-96
20.
Carter C.J., Pycock C.J. (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmac60: 267P-268P
21.
Casey D.E. (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology112 (Suppl. 1) : S55-S59
22.
Chiang C., Aston Jones G. (1993) Response of locus coeruleus neurons to footshock stimulation is mediated by neurons in the rostral ventral medulla. Neuroscience53: 705-715
23.
Chouinard G., Jones B., Remington G. et al. (1993) Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmac13: 25-40
24.
Costall B. (1993) The breadth of action of the 5HT3 receptor antagonists. Int Clin Psychopharmac8 (Suppl. 2): 3-9
25.
Costall B., Fortune D.H., Naylor R.J., Mardsen C.D., Pycock C. (1975) Serotoninergic involvement with neuroleptic catalepsy . Neuropharmacology14: 859-868
26.
Costall B., DomeneyA.M., Naylor R.J., Tyers M.B. (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmac92: 881-894
27.
Costall B., Domeney A.M., Naylor R.J. (1993) 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat. Neuroreport1: 77-80
28.
Cowen P. (1991) Serotonin receptor subtypes: implications for psychopharmacology . Br J Psychiat159 (Suppl. 12): 7-14
29.
Crow T.J. (1980) Molecular pathology of schizophrenia: More than one disease process? BMJ280: 66-68
30.
Curtis V.A., Wright P., ReveleyA., Kerwin R., LuceyJ.V. (1995) Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiat166: 642-646
31.
Curzon G., Kennett G.A. (1990) m-CPP: a tool for studying behavioural responses associated with 5-HT1C receptors. Trends Pharmac Sci11: 181-182
32.
Davis K.L., Kahn R.S., Ko G., Davidson M. (1991) Dopamine in schizophrenia: a review and reconceptualization . Am J Psychiat148:1474-1486
33.
Deakin J.F. (1991) Depression and 5-HT. Int Clin Psychopharmac6 (Suppl. 3): 23-28
34.
Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res4: 121-156
35.
Dewey S.L., Smith G.S., Logan J., Alexoff D., DingY.S., King P., Pappas N., Brodie J.D., Ashby C R J (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci15: 821-829
36.
Dubovsky S.L., Thomas M. (1995) Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiat56 (Suppl. 2): 38-48
37.
Duinkerke S.J., Botter P.A., Jansen A.A., van Dongen P.A., van Haaften A.J., Boom A.J., van Laarhoven J.H., Busard H.L. (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiat163: 451-455
38.
Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archs Gen Psychiat49: 538-544
39.
Farde L., Nordstrom A.L., Nyberg S., Halldin C., Sedvall G. (1994) D1-, D2-, and 5-HT2 -receptor occupancy in clozapine-treated patients. J Clin Psychiat55 (Suppl. B): 67-69
40.
Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. (1995) Positron emission tomography studies on D 2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmac15: 19S-23S
41.
Fibiger H., Miller J. (1977) An anatomical and electrophysiologic investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the cat. Neuroscience2: 975-987
42.
Gelders Y.G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiat155 (Suppl. 5): 33-36
43.
Gellman R.L., Aghajanian G.K. (1994) Serotonin 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience58: 515-525
44.
Glennon R.A., Dukat M. (1991) Serotonin receptors and their ligands: a lack of selective agents. Pharmac Biochem Behav40: 1009-1017
45.
Goldman-Rakic P.S., Lidow M.S., Gallager D.W. (1990) Overlap of dopaminergic, adrenergic, and serotonergic receptors and complementarity of their subtypes in primate prefrontal cortex . J Neurosci10: 2125-2138
46.
Gustafson E.L., Durkin M.M., Bard J.A., Zgombick J., Branchek T.A. (1996) A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-HT7 receptor in rat brain . Br J Pharmac117: 657-666
47.
Hervé D., Simon H., Blane G., LeMoal M., Glowinski J., Tassin J.P. (1981) Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesions of the median raphe in the rat. Brain Res216: 422-428
48.
Hervé D., Pickel V.M., Joh T.H., Beaudet A. (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons . Brain Res435: 71-83
49.
Hicks P.B. (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci47:1609-1615
50.
Hoyer D., Gozlan H., Bolanos F., Schechter L.E., Hamon M. (1989) Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact? Eur J Pharmac171: 137-139
51.
Hoyer D., Schoeffter P., Waeber C., Palacios J.M. (1990) Serotonin 5-HT1D receptors. Ann N YAcad Sci600:168-181
52.
Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmac Rev46:157-203
53.
Ichikawa J., Meltzer H.Y. (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmac281: 255-261
54.
Iqbal N., Asnis G.M., Wetzler S., Kahn R., Kay S.R., van Praag H.M. (1991) The MCPP challenge test in schizophrenia: hormonal and behavioural responses. Biol Psychiat30: 770-778
55.
Jenner P., Sheehy M., Marsden C.D. (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br J Clin Pharmac15 (Suppl. 2): 277S-289S
56.
Kahn R.S., Davidson M., Siever L., Gabriel S., Apter S., Davis K.L. (1993) Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiat150: 1337-1342
57.
Kane J., Honingfeld G., Stuger J. et al. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archs Gen Psychiat45: 789-796
58.
Kapur S., Remington G. (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiat153: 466-476
59.
Kerwin R.W. (1994) The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiat164:141-148
60.
Kilpatrick G.J., Jones B.J., Tyers M.B. (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature330: 746-748
Lappalainen J., Zhang L., Dena M., Oz M., Ozaki N., Yu D., Virkkunen M., Wieght F., Linnoila M., Goldman D. (1995) Identification, expression and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics27: 274-279
63.
Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Archs Gen Psychiat50: 810-818
64.
Leysen J.E., Niemegeers C J E, Tollenaere J.P., Laduron P.M. (1978) Serotonergic component of neuroleptic receptors . Nature272: 168
65.
Leysen J.E., Janssen P.M., Schotte U. et al. (1993) Interaction of antipsychotic drugs with neurotransmitter sites in vitro and in vivo in relation to pharmacological and chemical effects, role of 5-HT2 receptors. Psychopharmacology112 (Suppl.): S40-S54
66.
Leysen J.E., Janssen P.M., Megens A.A., Schotte A. (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiat55 (Suppl.): 5-12
67.
Link C G C, Arvanitis L., on behalf of the US Seroquel™ Group (1995) Seroquel treatment of hospitalized patients with acute exacerbation of chronic and subchronic schizophrenia. A multicentre, placebo-controlled, double-blind study. Eur Neuropsychopharmac5: 346
68.
Lovenberg T.W., Erlander M.G., Baron B.M., Rackne M., Slone A., Siegel B.W., Craft C.M., Burns JE, Danielson P.E., Sutcliffe J.G. (1993) Molecular cloning and functional expression of 5-HT1Elike rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA90: 2184-2188
69.
Lucas J.J., Hen R. ( 1996) New players in the 5-HT receptor field: genes and knockouts . Trends Pharmac Sci16: 246-252
70.
Marder S.R., Meibach R.C. (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat151: 825-835
71.
Mason S.L., Reynolds G.P. (1992) Clozapine has sub-micromolar affinity for 5-HT 1A receptors in human brain tissue. Eur J Pharmac221: 397-398
72.
McBain S.L., Dineen M., Weller M., Taylor S., Cooksey P., Williams P., Corn T. ( 1992) Ondansetron, a double-blind placebo-controlled study in acute schizophrenia. Schizophr Res6: 112
73.
Meltzer H.Y. (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology99: S18-S27
74.
Meltzer H.Y. (1991) Studies of ondansetron in schizophrenia. Biol Psychiat2: 891-893
75.
Meltzer H.Y. (1993) New drugs for the treatment of schizophrenia. Psychiat Clin N Am16: 365-385
76.
Meltzer H.Y. (1994) An overview of the mechanism of action of clozapine . J Clin Psychiat55 (Suppl. B): 47-52
77.
Meltzer HY, Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J.A. (1989a) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology99 (Suppl.): S68-S72
78.
Meltzer H.Y., Matsubara S., Lee J.C. (1989b) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmac Exp Therap251: 238-246
79.
Miller C.H., Fleischhacker W.W., Ehrmann H., Kane J.M. (1990) Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmac Bull26: 373-376
80.
Moghaddam B., Bunney B.S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from préfrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem54: 1755-1760
81.
Monferini E., Gaetani P., Rodriguez B., Giraldo E., Parenti M., Zocchetti A., Rizzi C.A. (1993) Pharmacological characterization of the 5-hydroxytryptamine receptor coupled to adenylyl cyclase stimulation in human brain. Life Sci52: PL61-PL65
82.
Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molec Pharmac43: 587-604
83.
Nash J.F., Meltzer H.G., Gudelsky G.H. (1988) Antagonism of serotonin receptor-mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmac191: 463-469
84.
Newcomer J.W., Faustman W.O., Zipursky R.B., Csernansky J.G. (1992) Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Archs Gen Psychiat49: 751-752
85.
Nomikos G.G., Zis A.P., Iumo M., Andersson J.L. (1994) Systematic administration of amperozide, a new atypical antipsychotic drug, preferentially depresses dopamine release in the rat medial frontal cortex. Psychopharmacology115: 147-156
86.
Nordstrom A.L., Farde L., Wiesel F-A., Forslund K., Pauli S., Halldin C., Uppfeldt G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects— a double blind PET study of schizophrenic patients. Biol Psychiat33: 227-235
87.
North R.A., Ushimara N. (1989) 5-Hydroxytryptamine acts at 5-HT2 receptors to decrease potassium conductance in rat nucleus accumbens neurones. J Physiol Lond417: 1-12
88.
Pazos A., Probst A., Palacios J.M. (1987a) Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin1 receptors. Neuroscience21: 97-122
89.
Pazos A., Probst A., Palacios J.M. (1987b) Serotonin receptors in the human brain—IV Autoradiographic mapping of serotonin2 receptors. Neuroscience21: 123-139
Peroutka S.J., Snyder S.H. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiat137: 1518-1522
92.
Peters J.A., Malone H.M., Lambert J.J. (1992) Recent advances in the electrophysiological characterization of 5-HT3 receptors. Trends Pharmac Sci13: 391-397
93.
Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M.H. (1992) Clinical and biologic response to clozapine in patients with schizophrenia: cross-over comparison with fluphenazine. Archs Gen Psychiat49: 345-353
94.
Pierce P.A., Peroutka S.J. (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology97: 118-122
95.
Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M., Verhoeff N.P., Kerwin R.W. (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet340: 199-202
96.
Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M.,Verhoeff N.P., Kerwin R.W. (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med23: 791-797
97.
Pilowsky L.S., Busatto G.F., Taylor M., Costa D.C., Sharma T., Sigmundsson T., Ell P.J., Nohria V., Kerwin R.W. (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine—a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology124:148-153
98.
Pompeiano M., Palacios J.M., Mengod G. (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT 2C receptors. Brain Res Molec Brain Res23: 163-178
99.
Potkin S.G., Weinberger D.R., Linnoila M., Wyatt R.J. (1983) Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiat140: 21-25
100.
Roth B.L., Ciaranello R.D., Meltzer H.Y. (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmac ExpTherap260:1361-1365
101.
Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F J, Jr. , Shen Y. , Meltzer HY, Sibley D.R. (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmac Exp Therap268: 1403-1410
102.
Sadzot B., Lemaire C., Maquet P., Salmon E., Plenevaux A., Degueldre C., Hermanne J.P., Guillaume M., Cantineau R., Comar D. et al. (1995) Serotonin 5-HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab15: 787-797
103.
Scherer J., Tatsch K., Schwarz J., Oertel W.H., Konjarczyk M., Albus M. (1994) D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiat Scand90: 266-268
104.
Schotte A., Janssen P F M, Gommeren W., Luyten W H M L, Van Gompel P., Lesage AS, DeLoore K., Leysen J.E. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology124: 57-73
105.
Seeman P. (1990) Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiat Scand358 (Suppl.): 14-20
106.
Seeman P., Lee T., Chau Wong M., Wong K. ( 1976) Antipsychotic drug doses and neuroleptic/dopamine receptors . Nature261: 717-719
107.
Sharp T., Bramwell S.R., Hjorth S., Grahame Smith D.G. (1989) Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis . Br J Pharmac98: 989-997
108.
Sheldon P.W., Aghajanian G.K. (1991) Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons. Synapse9: 208-218
109.
Sleight A.J., Carolo C., Petit N., Zwingelstein C., Bourson A. (1995) Identification of 5-hydroxytryptamine 7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatment . Molec Pharmac47: 99-103
110.
Sodhi M.S., Arranz M.J., Ball D., Sham P., Curtis D., Roberts G.W., Price J., Collier D.A., Kerwin R.W. (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport7:169-172
111.
Stephenson J.D. (1990) Neuropharmacological studies of the serotonergic system. Int Rev Psychiat2: 157-178
112.
Stocklin G. (1992) Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology. Eur J Nucl Med19: 527-551
113.
Stockmeier C.A., DiCarlo J.J., Zhang Y., Thompson P., Meltzer H.Y. (1993) Characterization of typical and atypical antipsychotic drugs basend on in vivo occupancy of serotonin 2 and dopamine 2 receptors . J Pharmac Exp Therap266: 1374-1384
114.
Targum S., Zborowski J., Henry M., Schmitz P., Sebree T., Wallin B. (1995) Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Eur Neuropsychopharmac5: 348
van Kammen D.P., McEvoy J.P., Targum S.D., Kardatzke D., Sebree T.B., Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology116: 168-175
117.
Waldmeier P.C., Delini-Stula A.A. (1979) Serotonin-dopamine interactions in the nigro-striatal system. Eur J Pharmac55: 363-373
118.
Wang R.Y., Ashby C.R., Edwards E., Zhang J.Y. (1994) The role of 5-HT3-like receptors in the action of clozapine. J Clin Psychiat55 (Suppl. B): 23-26
119.
Watling K.J., Beer M.S., Stanton J.A., Newberry N.R. (1990) Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmac182: 465-472
120.
Weinberger D.R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archs Gen Psychiat44: 660-669
121.
White A., Corn T.H., Feetham C., Faulconbridge C. (1991) Ondansetron in treatment of schizophrenia. Lancet337: 1173
122.
Wiesel F.A., Nordstrom A.L., Farde L., Eriksson B. (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology114: 31-38
123.
Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M.M., Gill M., Aschauer H., Nylander P-O., Macciardi F., Owen M.J. for the European Multicentre Association Study of Schizophrenia (1996) Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet347: 1294-1296
124.
Wilson M.A., Molliver M.E. (1991) The organization of serotonergic projections to cerebral cortex in primates: regional distribution of axon terminals. Neuroscience44: 537-553
125.
Wing L.L., Tapson G.S., Geyer M.A. (1990) 5HT2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology100: 417-425
126.
Wooley DW, Shaw E. ( 1954) A biological and pharmacological suggestion about certain mental disorders. Proc Nat Acad Sci USA40: 228-231
127.
Yamamoto B.K., Pehek E.A., Meltzer H.Y. (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiat55 (Suppl. B): 8-14
